Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049891 | 1.00 | DUT (0.46) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL15283677 | 0.95 | DUT (0.45) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL13575496 | 0.91 | DUT (0.46) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL12769575 | 0.90 | DUT (0.43) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL12049890 | 0.90 | DUT (0.43) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL25399447 | 0.90 | DUT (0.45) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL2105785 | 0.90 | DUT (0.45) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL17512783 | 0.90 | DUT (0.45) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL18721231 | 0.90 | DUT (0.45) | DUTP2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL15294576 | 0.88 | DUT (0.42) | DUTP2RY14P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7915232-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | DUT 88/4885P2RY14 1484/4885P2RY6 1891/4885 |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | NSUN2, RNGTT, RNMT | DUT 10/4885P2RY14 1297/4885P2RY6 1477/4885 |
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | DUT 30/4885P2RY14 1724/4885P2RY6 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.